Balchem Corporation (BCPC)
| Market Cap | 5.17B +2.8% |
| Revenue (ttm) | 1.06B +9.6% |
| Net Income | 158.08M +15.8% |
| EPS | 4.87 +16.8% |
| Shares Out | 32.13M |
| PE Ratio | 33.05 |
| Forward PE | 27.73 |
| Dividend | $0.96 (0.60%) |
| Ex-Dividend Date | Dec 23, 2025 |
| Volume | 96,913 |
| Open | 159.75 |
| Previous Close | 159.50 |
| Day's Range | 159.00 - 161.32 |
| 52-Week Range | 139.17 - 183.90 |
| Beta | 0.85 |
| Analysts | Buy |
| Price Target | 83.58 (-48.08%) |
| Earnings Date | Apr 30, 2026 |
About BCPC
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended ... [Read more]
Financial Performance
In 2025, Balchem's revenue was $1.04 billion, an increase of 8.75% compared to the previous year's $953.68 million. Earnings were $154.85 million, an increase of 20.53%.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for BCPC stock is "Buy." The 12-month stock price target is $83.58, which is a decrease of -48.08% from the latest price.
News
Balchem Earnings Call Transcript: Q1 2026
Record Q1 results with 8.1% revenue growth, strong gains across all segments, and robust cash flow. Branded ingredients and international expansion drive momentum, while inflation and geopolitical risks are managed through pricing and supply chain strategies.
Balchem reports Q1 adjusted EPS $1.33, consensus $1.33
Reports Q1 revenue $270.71M, consensus $266.5M. Ted Harris, Chairman, President and CEO of Balchem (BCPC) said, “The first quarter was an excellent start to the year for Balchem, with sales
Balchem Corporation Reports First Quarter 2026 Financial Results
MONTVALE, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2026 fiscal first quarter ended March 31, 2026.
Balchem Corporation Releases 2025 Sustainability Report
MONTVALE, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today published its 2025 Sustainability Report.
Balchem launches Metalosate T.E.A.M. plant tissue analysis platform
Balchem (BCPC) Plant Nutrition announced the launch of its Metalosate T.E.A.M. plant tissue analysis digital platform. “The platform helps advisors optimize nutrient balance to enhance yield potential...
Balchem Launches Metalosate® T.E.A.M.™ Plant Tissue Analysis Digital Platform to Deliver Research-Driven Nutrient Recommendations for Specialty Crops
MONTVALE, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Balchem Plant Nutrition, a global leader in chelated mineral plant nutrition and the maker of Metalosate® micronutrients, today announced the launch ...
Balchem Corporation to Participate in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026
MONTVALE, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in th...
Balchem Corporation to Participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026
MONTVALE, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in th...
Balchem Earnings Call Transcript: Q4 2025
Achieved record sales and earnings in 2025, with strong growth across all segments and robust international expansion. Q4 results showed double-digit sales and earnings increases, supported by strategic investments, disciplined capital allocation, and progress on sustainability goals.
Balchem reports Q4 adjusted EPS $1.31 vs $1.13 last year
Reports Q4 revenue $263.6M, consensus $259.59M. Ted Harris, Chairman, President, and CEO of Balchem (BCPC) said, “In the fourth quarter, Balchem’s strong growth trajectory continued. We delivered reco...
Balchem Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
MONTVALE, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2025 fiscal fourth quarter and full year ended December 31, 2025.
Balchem Corporation Announces Quarterly Conference Call for Fourth Quarter and Full Year 2025 Financial Results on February 20, 2026
MONTVALE, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, February 20, 2026, at 11:00 AM Eastern Time (ET) to ...
Balchem issues statement on new EU choline chloride anti-dumping measures
As producers of choline chloride in the EU, Eastman and Balchem (BCPC) welcome the European Union’s decision published on December 19, 2025 to adopt anti-dumping duties between 90.0 and 115.9%
Statement on new EU choline chloride anti-dumping measures
MONTVALE, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- As producers of choline chloride in the EU, Eastman and Balchem welcome the European Union's decision published on December 19, 2025 to adopt anti-dum...
Balchem initiated with a Neutral at Rothschild & Co Redburn
Rothschild & Co Redburn initiated coverage of Balchem (BCPC) with a Neutral rating and $162 price target The company has a “resilient” business model built upon niche high-growth products, the
Balchem Corporation to Present at Baird's 55th Annual Global Industrial Conference on November 12, 2025
MONTVALE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at Baird'...
Balchem management to meet with Clear Street
Meeting to be held in Kansas City on October 28 hosted by Clear Street.
Balchem price target raised to $190 from $189 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Balchem (BCPC) to $190 from $189 and keeps a Buy rating on the shares. The firm remains confident in Balchem’s long-term prospects
Balchem Earnings Call Transcript: Q3 2025
Record Q3 2025 results with double-digit sales and earnings growth across all segments, driven by strong demand for specialty nutrients and better-for-you trends. Continued margin expansion, robust cash flow, and positive outlook supported by new capacity investments and international growth.
Balchem reports Q3 adjusted EPS $1.35 vs $1.13 last year
Reports Q3 revenue $267.6M, consensus $258.28M. Ted Harris, Chairman, President and CEO of Balchem (BCPC) said, “In the third quarter, our company continued to deliver strong growth, fueled by the
Scoring Big With Fans: Balchem Spotlights the Power of Vitamin K2 at FC Bayern Women's Season Opener
MONTVALE, N. J.--(BUSINESS WIRE)--Balchem, a global manufacturer of specialty ingredients for human nutrition, has launched its first direct-to-consumer initiative.
Balchem Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025
MONTVALE, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at the H....
Balchem Transcript: Status Update
Metabolic flexibility in dairy cattle allows for tailored protein nutrition strategies to improve nitrogen efficiency and sustainability. Glucogenic energy sources enhance milk protein yield, while optimizing rumen protein balance and amino acid profiles can reduce nitrogen excretion. New products and ongoing research aim to further advance efficiency and sustainability.
Balchem price target raised to $189 from $180 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Balchem (BCPC) to $189 from $180 and keeps a Buy rating on the shares. The company reported Q2 beat and its future
Balchem Earnings Call Transcript: Q2 2025
Record Q2 2025 results with 9.1% revenue growth, strong performance across all segments, and robust margins. Strategic investments in capacity and science, plus favorable regulatory changes, support a positive outlook for continued growth.